January 22, 2018 / 2:12 PM / 4 months ago

BRIEF-Ligand Enters Into Worldwide Omniab Platform License Agreement With Ferring Pharmaceuticals

Jan 22 (Reuters) - Ligand Pharmaceuticals Inc:

* LIGAND ENTERS INTO WORLDWIDE OMNIAB® PLATFORM LICENSE AGREEMENT WITH FERRING PHARMACEUTICALS

* LIGAND PHARMACEUTICALS INC - ‍UNDER LICENSE, FERRING WILL BE ABLE TO USE FULL OMNIAB PLATFORM TO DISCOVER FULLY HUMAN MONO- AND BISPECIFIC ANTIBODIES​

* LIGAND PHARMACEUTICALS INC - ‍FERRING WILL BE RESPONSIBLE FOR ALL COSTS RELATED TO PROGRAMS​

* LIGAND PHARMACEUTICALS-WITH DEAL WITH FERRING, CO‍ ELIGIBLE TO RECEIVE ANNUAL PLATFORM ACCESS PAYMENTS, DEVELOPMENT AND REGULATORY MILESTONE PAYMENTS​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below